GlobalData on MSN1d
Microbiotica initiates subject dosing in Phase Ib melanoma therapy trial
Microbiotica has dosed the first subject in the Phase Ib MELODY-1 clinical trial of MB097, a precision microbiome co-therapy ...
Business Weekly1d
Microbiotica progresses melanoma trial
Wellcome Sanger Institute spin-out Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision ...
PharmiWeb1d
Microbiotica Announces First Patient Dosed in its International Phase 1b Trial, MELODY-1 of MB097 Precision Microbiome Co-Therapy in Advanced Melanoma
Being Tested in Combination with MSD’s anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab) Cambridge, UK – 10 October 2024: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral ...
Nature1y
Microbiotica—unlocking the microbiome as a multi-therapeutic modality
Microbiotica was founded in 2016 in Cambridge, UK, to translate pioneering research from the Wellcome Sanger Institute into novel, microbiome-based precision medicines. It has developed the ...
Business Insider1mon
Microbiotica’s Microbiome Medicines in Melanoma and Ulcerative Colitis Gain Regulatory Approvals in EU and UK for Phase 1b Studies
CAMBRIDGE, United Kingdom, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Microbiotica, a biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products ...
pharmaphorum1mon
UK spin-out Microbiotica wants to be world leader in microbiome drugs
Microbiotica is a spin-out from the not-for-profit Wellcome Trust Sanger Institute (pictured) which specialises in genome sequencing and has been researching the microbiome since 2010. The UK ...
MedPage Today on MSN13d
Novel Monoclonal Antibody Shows Promise in Ulcerative Colitis
Tulisokibart is a tumor necrosis factor (TNF)-like cytokine 1A (TL1A) monoclonal antibody with a different mechanism of ...
Outsourcing-pharma7d
Microbiome startup Sequentia Biotech heralds “new era” in omics with €10 million round
The Barcelona-based startup Sequentia Biotech has raised €10 million ($11 million) in a Series A round to finance the ...
icr.ac.uk1d
Multi-million-pound UK-wide platform into cancer immunotherapy launches
A new multimillion-pound research programme, involving scientists from The Institute of Cancer Research, London, is aiming to ...
Nature3y
Translating precision in microbiome science into predictive biomarkers and more effective drugs
Yet, there remain technical barriers to predictable translation in this emerging field. Microbiotica is addressing the barriers and helping drive a new era of rigorous, data-driven microbiome R&D.